PHF19 and Akt control the switch between proliferative and invasive states in melanoma

Cell Cycle

Volumn 11, Issue 8, 2012, Pages 1634-1645

  Ghislin, Stephanie ^a   Deshayes, Frederique ^a   Middendorp, Sandrine ^a   Boggetto, Nicole ^a   Alcaide Loridan, Catherine ^a  

^a INSTITUT JACQUES MONOD   (France)

Author keywords

Akt; Melanoma; Nanog; Oct4; PHF19; Transmigration

Indexed keywords

PHD FINGER PROTEIN 19; PHOSPHOPROTEIN; POLYCOMB GROUP PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ARTICLE; CANCER INVASION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MELANOMA CELL; MICROARRAY ANALYSIS; NANOG GENE; NERVE CELL; OCT4 GENE; PHENOTYPIC VARIATION; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 84860342728     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20095     Document Type: Article

References (43)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010; 60:277-300; PMID:20610543; http://dx.doi.org/10.3322/caac.20073.
2. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 2009; 23:488-96; PMID:19544689.
3. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 2005; 102:6092-7; PMID:15833814; http://dx.doi.org/10.1073/pnas. 0501564102.
4. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 2006; 19:290-302; PMID:16827748; http://dx.doi.org/10.1111/j.1600-0749.2006.00322.x.
5. Hoek KS, Eichhoff OM, Schlegel NC, Döbbeling U, Kobert N, Schaerer L, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 2008; 68:650-6; PMID:18245463; http://dx.doi.org/10. 1158/0008-5472.CAN-07-2491.
6. Hoek KS, Goding CR. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 2010; 23:746-59; PMID:20726948; http://dx.doi.org/10.1111/j.1755-148X.2010.00757.x.
7. Mitchison TJ. The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 2012; 23:1-6; PMID:22210845; http://dx.doi.org/10.1091/mbc.E10- 04-0335.
8. Ramgolam K, Lauriol J, Lalou C, Lauden L, Michel L, de la Grange P, et al. Melanoma spheroids grown under neural crest cell conditions are highly plastic migratory/invasive tumor cells endowed with immunomodulator function. PLoS One 2011; 6:18784; PMID:21526207; http://dx.doi.org/10.1371/journal.pone. 0018784.
9. Ghislin S., Deshayes F., Lauriol J., Middendorp S., Martins I., Al-Daccak R.and Alcaide-Loridan C. Plasticity of melanoma cells induced by neural cell crest conditions and three-dimensional growth. Mel. Res. 2012. http:dx.doi.org/10.1097/CMR.0b013e328351e7c4
10. Wang S, Robertson GP, Zhu J. A novel human homologue of Drosophila polycomblike gene is upregulated in multiple cancers. Gene 2004; 343:69-78; PMID:15563832; http://dx.doi.org/10.1016/j.gene.2004.09.006.
11. Coles AH, Jones SN. The ING gene family in the regulation of cell growth and tumorigenesis. J Cell Physiol 2009; 218:45-57; PMID:18780289; http://dx.doi.org/10.1002/jcp.21583.
12. Li J, Martinka M, Li G. Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis 2008; 29:1373-9; PMID:18375955; http://dx.doi.org/10.1093/carcin/bgn086.
13. Cheli Y, Giuliano S, Botton T, Rocchi S, Hofman V, Hofman P, et al. Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 2011; 30:2307-18; PMID:21278797; http://dx.doi.org/10.1038/onc.2010.598.
14. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010; 141:583-94; PMID:20478252; http://dx.doi.org/10.1016/j.cell.2010.04.020.
15. Boulay G, Rosnoblet C, Guérardel C, Angrand PO, Leprince D. Functional characterization of human Polycomb-like 3 isoforms identifies them as components of distinct EZH2 protein complexes. Biochem J 2011; 434:333-42; PMID:21143197; http://dx.doi.org/10.1042/BJ20100944.
16. Wang R, Brattain MG. AKT can be activated in the nucleus. Cell Signal 2006; 18:1722-31; PMID:16616456; http://dx.doi.org/10.1016/j.cellsig.2006.01. 020.
17. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003; 2:339-45; PMID:12851486; http://dx.doi.org/10.4161/cc.2.4.433.
18. Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 2009; 28:843-53; PMID:19079346; http://dx.doi.org/10.1038/onc.2008.433.
19. Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H, et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol 2007; 27:5105-19; PMID:17502350; http://dx.doi.org/10.1128/MCB.00162-07.
20. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:624-9; PMID:12374981; http://dx.doi.org/10. 1038/nature01075.
21. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100:11606-11; PMID:14500907; http://dx.doi.org/10.1073/pnas.1933744100.
22. Wei Y, Chen YH, Li LY, Lang J, Yeh SP, Shi B, et al. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol 2011; 13:87-94; PMID:21131960; http://dx.doi.org/10.1038/ncb2139.
23. Bryant RJ, Winder SJ, Cross SS, Hamdy FC, Cunliffe VT. The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells. Prostate 2008; 68:255-63; PMID:18095286; http://dx.doi.org/10.1002/pros.20705.
24. Abdullah C, Wang X, Becker D. Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma. Cell Cycle 2011; 10:977-88; PMID:21358262; http://dx.doi.org/10.4161/cc.10.6.15079.
25. Chawla R, Procknow JA, Tantravahi RV, Khurana JS, Litvin J, Reddy EP. Cooperativity of Cdk4R24C and Ras in melanoma development. Cell Cycle 2010; 9:3305-14; PMID:20703083; http://dx.doi.org/10.4161/cc.9.16.12632.
26. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298:1039-43; PMID:12351676; http://dx.doi.org/10.1126/science.1076997.
27. Madhunapantula SV, Robertson GP. The PTENAKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res 2009; 22:400-19; PMID:19493313; http://dx.doi.org/10.1111/j.1755-148X.2009.00585.x.
28. Caputo E, Maiorana L, Vasta V, Pezzino FM, Sunkara S, Wynne K, et al. Characterization of human melanoma cell lines and melanocytes by proteome analysis. Cell Cycle 2011; 10:2924-36; PMID:21857157; http://dx.doi.org/10.4161/ cc.10.17.17068.
29. Villares GJ, Zigler M, Bar-Eli M. The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis - a possible therapeutic target. Oncotarget 2011; 2:8-17; PMID:21378407.
30. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005; 120:303-13; PMID:15707890; http://dx.doi.org/10. 1016/j.cell.2004.12.018.
31. Liu Y, Denlinger CE, Rundall BK, Smith PW, Jones DR. Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65. J Biol Chem 2006; 281:31359-68; PMID:16926151; http://dx.doi.org/10.1074/jbc.M604478200.
32. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci 2007; 120:2479-87; PMID:17646672; http://dx.doi.org/10.1242/jcs.001222.
33. Sun L, Zhao H, Xu Z, Liu Q, Liang Y, Wang L, et al. Phosphatidylinositol- 3-kinase/protein kinase B pathway stabilizes DNA methyltransferase I protein and maintains DNA methylation. Cell Signal 2007; 19:2255-63; PMID:17716861; http://dx.doi.org/10.1016/j.cellsig.2007.06.014.
34. Eichhoff OM, Weeraratna A, Zipser MC, Denat L, Widmer DS, Xu M, et al. Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigment Cell Melanoma Res 2011; 24:631-42; PMID:21599871; http://dx.doi.org/10.1111/j.1755-148X.2011.00871.x.
35. Hu T, Li C. Convergence between Wnt-β-catenin and EGFR signaling in cancer. Mol Cancer 2010; 9:236; PMID:20828404; http://dx.doi.org/10.1186/1476- 4598-9-236.
36. Bordonaro M, Tewari S, Cicco CE, Atamna W, Lazarova DL. A switch from canonical to noncanonical Wnt signaling mediates drug resistance in colon cancer cells. PLoS One 2011; 6:27308; PMID:22073312; http://dx.doi.org/10.1371/ journal.pone.0027308.
37. Javelaud D, Alexaki VI, Pierrat MJ, Hoek KS, Dennler S, Van Kempen L, et al. GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells. Pigment Cell Melanoma Res 2011; 24:932-43; PMID:21801332; http://dx.doi.org/10.1111/j.1755- 148X.2011.00893.x.
38. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007; 43:935-46; PMID:17320377; http://dx.doi.org/10. 1016/j.ejca.2007.01.017.
39. Wong CE, Paratore C, Dours-Zimmermann MT, Rochat A, Pietri T, Suter U, et al. Neural crest-derived cells with stem cell features can be traced back to multiple lineages in the adult skin. J Cell Biol 2006; 175:1005-15; PMID:17158956; http://dx.doi.org/10.1083/jcb.200606062.
40. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8; PMID:11846609; http://dx.doi.org/10.1006/meth.2001.1262.
41. Ghislin S, Obino D, Middendorp S, Boggetto N, Alcaide-Loridan C, Deshayes F. Junctional adhesion molecules are required for melanoma cell lines transendothelial migration in vitro. Pigment Cell Melanoma Res 2011; 24:504-11; PMID:21466663; http://dx.doi.org/10.1111/j.1755-148X.2011.00856.x.
42. Martins I, Deshayes F, Baton F, Forget A, Ciechomska I, Sylla K, et al. Pathologic expression of MHC class II is driven by mitogen-activated protein kinases. Eur J Immunol 2007; 37:788-97; PMID:17304627; http://dx.doi.org/10. 1002/eji.200636620.
43. Mukhopadhyay A, Deplancke B, Walhout AJM, Tissenbaum HA. Chromatin immunoprecipitation (ChIP) coupled to detection by quantitative real-time PCR to study transcription factor binding to DNA in Caenorhabditis elegans. Nat Protoc 2008; 3:698-709; PMID:18388953; http://dx.doi.org/10.1038/nprot.2008.38.